News
Japanese drugmakers addressing neglected tropical diseases, and not just out of altruism
The GHIT Fund and Japanese pharma partners Astellas and Esai were featured in the Jiji Press/Japan Times on January 6. Japans' pharmaceutical companies see their engagement in drug development for neglected diseases in the developing world as a sustainable "business for the future", not as philanthropy. GHIT's work has been a critical catalyst.